In addition, the NEOSUMMIT-01 trial, a randomized phase II study in China, evaluated the addition of the PD-1 inhibitor toripalimab to chemotherapy for cT3-4aN+M0 resectable gastric cancer. The gene discussed is PDCD1; the disease is gastric cancer.